Conference call to be held June 11 at 11:00 a.m. ET "We are very encouraged by the early and promising data from our first neoantigen-directed immunotherapy, ADXS-NEO" PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery,

PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the company will host a business update call on Tuesday, June 11, 2019 at 11:00 a.m. ET.

"The Advaxis team worked diligently to provide a comprehensive response back to the FDA’s requests for additional CMC information, and through constructive dialogue, we successfully resolved the partial clinical hold" PRINCETON, N.J.--( BUSINESS WIRE )--   Advaxis, Inc.

Updated data from Phase 1/2 ADXS-PSA study combination arm show prolonged survival in heavily pretreated prostate cancer patients with microsatellite-stable (MSS) disease Updated early findings from Phase 1 ADXS-NEO study show encouraging safety, immunogenicity and clinical signals in MSS

"It is with mixed emotions that I leave my role as the Chief Scientific Officer, however, I am excited to continue providing scientific guidance to Advaxis as we progress toward clinical validation of the platform in furtherance of Advaxis’ mission to improve the lives of people with cancer."

PRINCETON, N.J.--( BUSINESS WIRE )--   Advaxis, Inc.    (NASDAQ: ADXS) , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces participation in five upcoming industry conferences: BioNJ 9 th  Annual BioPartnering

PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of 2,500,000 shares of its

PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it intends to offer and sell in an underwritten public offering shares

Updated Results from Phase 1/2 Study to be Presented Today at the AACR Annual Meeting "We are very excited to report the updated ADXS-PSA data today at the AACR meeting" PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.    (NASDAQ: ADXS) , a late-stage biotechnology company focused on the

Data to be Presented at AACR Annual Meeting "This is the first presentation of clinical data from our ADXS-NEO program at a major medical conference. We are continuing to enroll subjects and gather additional clinical and immune correlative data, and plan to share updated data from this study